Confocal Microscopy Dual Band in the Management of Bladder Cancer

Overview

Bladder cancer is one of the most common cancer worldwide and the second most frequent urological cancer. The photodynamic diagnosis technique (PDD) currently used (Hexvix®) has improved tumor detection but with a high false positive rate. Indeed, the main limitation of the PDD is its lack of specificity, ranging from 35 to 66%. The association of this technique with new technologies such as the Cellvizio Dual Band featuring simultaneous dual wavelength illumination and detection, could improve the identification of tumoral lesions. The objective of this study is to demonstrate the efficacy of Cellvizio dual band technique for the diagnosis of tumors bladders.

Full Title of Study: “Study of the Contribution of Confocal Microscopy Dual Band in the Management of Bladder Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: September 2016

Interventions

  • Device: Cellvizio dual band
    • Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.

Arms, Groups and Cohorts

  • Bladder tumor resection

Clinical Trial Outcome Measures

Primary Measures

  • Determination of the nucleo-cytoplasmic ratio of cells
    • Time Frame: at inclusion
    • In order to perform comparison between benign versus malignant cytology, significant differences between cytoplasmic areas and nuclear areas will be determine to stablish a value of nucleo-cytoplasmic ratio

Secondary Measures

  • Number of neoplastic lesions identified by Cellvizio compared to number of lesions identified by pathology
    • Time Frame: through the study completion, an average of 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patients having 18 years old or more – Patients with a bladder carcinoma and with indication of tumor resection under Hexvix procedure. – Patients giving consent to participate in the study Exclusion Criteria:

-No consent to participate in the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Lille Catholic University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean-Louis Bonnal, MD, Principal Investigator, Service d’Urologie, Groupement des hôpitaux de l’Institut Catholique de Lille

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.